Search Results - "Bastholt L"

Elevated neutrophil and monocyte counts in peripheral blood are associated with poor survival in patients with metastatic melanoma: a prognostic model.

Authors: Schmidt, H. Bastholt, L. Geertsen, P. et al.

Source: British Journal of Cancer. 8/8/2005, Vol. 93 Issue 3, p273-278. 6p.

Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial.

Authors: Overgaard J Hansen HS Specht L et al.

Source: Lancet. 9/20/2003, Vol. 362 Issue 9388, p933-940. 8p.

Validation of the PHEEM instrument in a Danish hospital setting.

Authors: Aspegren, K. Bastholt, L. Bested, K.M. et al.

Source: Medical Teacher. Jun2007, Vol. 29 Issue 5, p504-506. 3p. 2 Charts.

Subject Terms: *Education, *Culture, *Factor analysis, Hospitals, Danish language, Physicians

1207 - EURO-VOYAGE: Effectiveness and safety of ipilimumab (IPI) administered during a European Expanded Access Programme (EAP) in patients with advanced melanoma (MEL).

Authors: Ascierto, P. Bastholt, L. Mohr, P. et al.

Source: European Journal of Cancer. Feb2017 Supplement 1, Vol. 72, pS128-S128. 1p.

SP-0197: The role of radiotherapy in modern melanoma treatment.

Authors: Bastholt, L. Bahij, R.

Source: Radiotherapy & Oncology. 2014 Supplement, Vol. 111, pS79-S79. 1p.

Subjects: Cancer radiotherapy, Cancer treatment, Cancer research, Oncology periodicals, Periodical articles

An update on access to novel treatment for metastatic melanoma in Europe — A 2024 survey of the European melanoma registry and the European association of dermato-oncology.

Authors: Kandolf, L. Ascierto, P.A. Bastholt, L. et al.

Source: European Journal of Cancer. Feb2025, Vol. 216, pN.PAG-N.PAG. 1p.

Small molecules and targeted therapies in distant metastatic disease.

Authors: Hersey, P. Bastholt, L. Chiarion-Sileni, V. et al.

Source: Annals of Oncology. Aug2009 Supplement 6, Vol. 20 Issue suppl_6, pvi35-vi40. 1p.

1104P Efficacy of immune checkpoint inhibition in metastatic or non-resectable melanoma after failure of adjuvant anti-PD1 treatment: A EUMelareg real-world evidence study.

Authors: Weichenthal, M. Schadendorf, D. Bastholt, L. et al.

Source: Annals of Oncology. 2023 Supplement 2, Vol. 34, pS665-S666. 2p.

Health-related quality of life in patients with high-risk melanoma randomised in the Nordic phase 3 trial with adjuvant intermediate-dose interferon alfa-2b

Authors: Brandberg, Y. Aamdal, S. Bastholt, L. et al.

Source: European Journal of Cancer. Sep2012, Vol. 48 Issue 13, p2012-2019. 8p.

1699eP Treatment patterns using encorafenib plus binimetinib in BRAF mutated melanoma patients.

Authors: Mohr, P. Weichenthal, M. Asher, N. et al.

Source: Annals of Oncology. 2025 Supplement 2, Vol. 36, pS1000-S1001. 2p.

1676P Early discontinuation of immunotherapy in patients with objective responses: Clinical outcomes in real-world Danish patients with advanced melanoma.

Authors: Jurlander, R.S. Donia, M. Borch, T.H. et al.

Source: Annals of Oncology. 2025 Supplement 2, Vol. 36, pS991-S992. 2p.

1647P Dabrafenib/trametinib versus encorafenib/binimetinib in BRAF-mutant metastatic melanoma: A real-world propensity score matched survival analysis.

Authors: Garitaonaindía Díaz, Y. Khan, S. Friis, R.B. et al.

Source: Annals of Oncology. 2025 Supplement 2, Vol. 36, pS977-S978. 2p.

1646P Efficiency of second-line BRAF/MEK inhibitors in BRAFV600 mutated metastatic melanoma patients after first-line immunotherapy failure: A EUMelaReg real-world study.

Authors: Ellebaek, E. Weichenthal, M. Gavrilova, I. et al.

Source: Annals of Oncology. 2025 Supplement 2, Vol. 36, pS976-S977. 2p.

1623P Impact of switching from BRAF/MEK inhibition to immune checkpoint inhibition before secondary resistance in metastatic melanoma: A EUMelaReg real-world study.

Authors: Weichenthal, M. Gavrilova, I. Mangana, J. et al.

Source: Annals of Oncology. 2025 Supplement 2, Vol. 36, pS963-S964. 2p.

830P Efficacy of immunotherapy in melanoma patients with symptomatic brain metastases treated with steroids: Initial report from the MEMBRAINS trial.

Authors: Borch, T.H. Schmidt, H. Bastholt, L. et al.

Source: Annals of Oncology. 2022 Supplement 7, Vol. 33, pS928-S928. 1p.

A phase II study of thalidomide and temozolomide in patients with brain metastases from malignant melanoma: lymphopenia correlates with response.

Authors: Vestermark, L. W. Holtved, E. Dahlrot, R. et al.

Source: Ecancermedicalscience. 2008, Vol. 2, p1-12. 12p. 2 Charts, 3 Graphs.

1642P The role of BRAF/MEKi rechallenge in BRAFV600 mutated melanoma patients: Insights from a EUMelaReg real-world study.

Authors: Gavrilova, I. Weichenthal, M. Asher, N. et al.

Source: Annals of Oncology. 2025 Supplement 2, Vol. 36, pS974-S974. 1p.

1547P Clinical outcomes of patients with acquired resistance to checkpoint inhibitors in melanoma, renal cell carcinoma and non-small cell lung cancer.

Authors: Syberg, M.J. Andersen, R. Presti, M. et al.

Source: Annals of Oncology. 2025 Supplement 2, Vol. 36, pS924-S924. 1p.

Which medical disciplines diagnose and treat melanoma in Europe in 2019? A survey of experts from melanoma centres in 27 European countries.

Authors: Kandolf‐Sekulovic, L. Peris, K. Stratigos, A. et al.

Source: Journal of the European Academy of Dermatology & Venereology. May2021, Vol. 35 Issue 5, p1119-1132. 14p.

1109P Association of clinical features with long-term survival in patients with melanoma who responded to distinct checkpoint inhibitors.

Authors: Ellebaek, E. Khan, S. Borch, T.H. et al.

Source: Annals of Oncology. 2024 Supplement 2, Vol. 35, pS734-S735. 2p.